Loading...
•
Dec 31, 2019
Standard Biotool Q4 2019 Earnings Report
Announced fourth quarter and full year financial results.
Key Takeaways
Fluidigm Corporation reported strong sequential quarterly growth in Q4 2019, driven by customer adoption of Imaging Mass Cytometry™ and launched over 10 new products for the mass cytometry business.
Fourth quarter revenue reached $32.4 million.
Full year 2019 revenue increased 4 percent to $117.2 million.
Full year mass cytometry revenue increased 23 percent.
Covance selected Fluidigm CyTOF technology to develop highly multiplexed human immune profiling services.
Standard Biotool
Standard Biotool
Forward Guidance
Fluidigm expects to advance mass cytometry technology further into the health care ecosystem while reinvigorating their microfluidics franchise and are well-positioned for accelerating growth, particularly in the latter part of the year.